Holen Sie sich die Stockscreener-App
13.96
1.06%
-0.15
Handel nachbörslich:
14.03
0.07
+0.50%
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - Bluefield Daily Telegraph
Biohaven stock hits 52-week low at 14.32 USD By Investing.com - Investing.com India
Biohaven (BHVN) Price Target Lowered by JPMorgan to $55 | BHVN S - GuruFocus
Biohaven (BHVN) Target Price Lowered by JP Morgan Analyst | BHVN Stock News - GuruFocus
Biohaven (BHVN) Price Target Lowered by JPMorgan to $55 | BHVN Stock News - GuruFocus
Biohaven price target lowered to $55 from $68 at JPMorgan - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. ... - Bluefield Daily Telegraph
Biohaven Insiders Added US$6.28m Of Stock To Their Holdings - Yahoo Finance
Investigation Underway: Biohaven Ltd. (BHVN)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire
New Haven-based bioscience firms Bexorg, Biohaven agree to collaborate - Hartford Business Journal
BHVN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Biohaven Ltd. - ACCESS Newswire
Biohaven (BHVN) Teams Up with Bexorg for CNS Disorder Research C - GuruFocus
Kalkine : Biohaven Ltd Shift Amid Sector Moves and Earnings Per Share Focus - Kalkine Media
Biohaven, Bexorg Collaborate to Develop CNS Therapies - MarketScreener
Biohaven (BHVN) Teams Up with Bexorg for CNS Disorder Research Collaboration | BHVN Stock News - GuruFocus
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development - The Manila Times
Bexorg announces multi-program research collaboration with Biohaven - TipRanks
Bexorg Announces Research Collaboration with Biohaven - GlobeNewswire
Biohaven Ltd. (NYSE:BHVN) Shares Purchased by Parallel Advisors LLC - Defense World
Levi & Korsinsky Investigates Possible Securities Fraud by Biohaven Ltd. (BHVN) - ACCESS Newswire
Fraud Investigation: Levi & Korsinsky Investigates Biohaven Ltd. (BHVN) on Behalf of Shareholders - ACCESS Newswire
Levi & Korsinsky Investigating Whether Biohaven Ltd. (BHVN) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - GlobeNewswire Inc.
Ongoing Biohaven Ltd. (BHVN) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Biohaven Ltd. Highlights Strategic Focus in Investor Presentation - MSN
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Biohaven Ltd. (BHVN) - ACCESS Newswire
Sector Update: Health Care - marketscreener.com
Biohaven Shares Rise on Drug Pipeline Update With Two Near-Market Candidates - marketscreener.com
Shareholders Alert: Investigation Into Biohaven Ltd. (BHVN)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Biohaven Ltd.: Promising Pipeline and Undervaluation Justify Buy Rating - TipRanks
Jim Cramer on Biohaven Ltd. (BHVN): “I Think That This is a Buy” - Insider Monkey
Jim Cramer’s Thoughts on These 10 Stocks - Insider Monkey
Biohaven Lands Major $600 Million Deal With Oberland Capital - Finimize
How To Trade (BHVN) - news.stocktradersdaily.com
Biohaven Ltd. Receives Buy Rating Amidst Promising Developments and Strategic Advancements - TipRanks
Biohaven stock hits 52-week low at $14.36 amid market challenges By Investing.com - Investing.com South Africa
Morgan Stanley maintains Biohaven stock with $63 target - Investing.com Australia
BHVN Investor Notice: Levi & Korsinsky Investigates Biohaven Ltd. for Securities Law Violations - ACCESS Newswire
Biohaven stock hits 52-week low at $14.36 amid market challenges - Investing.com Nigeria
H.C. Wainwright maintains Buy on Biohaven stock, $54 price target - Investing.com Australia
H.C. Wainwright maintains Buy on Biohaven stock, $54 price target By Investing.com - Investing.com India
Biohaven Ltd. Receives Buy Rating from Douglas Tsao Amid Promising R&D Advancements and Strategic Developments - TipRanks
Investors in Biohaven Ltd. (BHVN) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Cowen reiterates Buy on Biohaven stock, maintains $75 target By Investing.com - Investing.com South Africa
Biohaven Ltd. Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - MarketScreener
Cowen reiterates Buy on Biohaven stock, maintains $75 target - Investing.com
Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug - GuruFocus
Biohaven initiates global Phase 2/3 study of BHV-8000 - TipRanks
Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug Trial | BHVN Stock News - GuruFocus
TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'This Pipeline Is Impressive', 'Buy BHVN' - StreetInsider
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):